Expertise

Current and Previous Roles of Glen Clack

Translational and early clinical development of anti-cancer agents, from lead optimisation to clinical proof of concept in solid and haematological malignancies; both as monotherapy and combination with other anti-cancer treatments including small molecules, chemotherapy, radiotherapy and immune oncology agents.

The relevant biological effect areas of these compounds have included hormone manipulation, invasion, DNA damage repair, immune modulation, angiogenesis, MTOR/PI3K/AKT and MET pathways, anti-sense oligonucleotide, and tumour genetic drivers.

This includes the overall clinical, scientific & value content, risk benefit assessment and delivery of the medical science components to the projects to time & quality, the translational and clinical strategy, ethical and scientific integrity of the plans, studies and the product, and the risk management plan.

Skills

Provision of strategic advice in early phase clinical development
Global drug development experience through all phases of drug development
Development of small and large molecule anti-cancer compounds; as monotherapy and in combination with other anti-cancer treatments, including radiotherapy, in both solid and haematological malignancies
Experience of compounds in the following biological effect areas:
- Endocrine manipulation
- Tumour invasion
- DNA damage repair
- Immune modulation
- Angiogenesis
- MTOR/PI3K/AKT pathway
- Anti-sense oligonucleotide
- Cancer vaccines
- Tumour genetic drivers
- Thymidylate synthase inhibitors
Collaboration with regulatory authorities and academics to produce highly flexible and adaptive early phase clinical trial designs, that allow clinical studies to evolve in line with emerging data. These designs have been shown to be both faster in delivering proof of concept and more efficient
Delivery of US, European and Japanese regulatory submissions
Orphan status and accelerated approval opportunities
Active liaison with regulatory authorities, research groups and key opinion leaders

2020-Present

Chief Medical Officer

Modulus Oncology Ltd.

2020-Present

Oncology Drug Development Advisor

Cumulus Oncology Ltd.

2015-Present

Managing Director

Ailse Oncology Ltd., Lyme Green, Cheshire

2016-Present

Honorary Professor of Translational Medicine

Department of Oncology and Metabolism, Faculty of Medicine, University of Sheffield

2008-Present

MSc Module Tutor

'Introduction to Clinical Trials' modules of the Pharmaceutical Industry Advanced Training (PIAT) MSc and Model Based Drug Development MSc.

The School of Pharmacy and Pharmaceutical Sciences, Manchester University

2007-Present

Honorary Lecturer, Translational Science

The School of Medicine and School of Pharmacy, Manchester University

2004-2016

Honorary Research Fellow

The Section of Human Metabolism, Division of Clinical Sciences (North), Faculty of Medicine, University of Sheffield

2013-2016

Senior Medical Director, Oncology Translational Medicine Unit